BIOMARIN PHARMACEUTICAL INC - DISCONTINUES DEVELOPMENT OF BMN 349, ORAL THERAPEUTIC FOR ALPHA-1 ANTITRYPSIN DEFICIENCY (AATD) - SEC FILING

Reuters · 2d ago

Please log in to view news